Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation

Allison N DuRoss; Madeleine R Landry; Charles R Thomas Jr; Megan J Neufeld; Conroy Sun

doi:10.1016/j.dib.2021.107394

Preclinical data on co-delivery of temozolomide and talazoparib by fucodain-coated nanoscale metal organic frameworks for colorectal cancer chemoradiation

Data Brief. 2021 Sep 22:38:107394. doi: 10.1016/j.dib.2021.107394. eCollection 2021 Oct.

Authors

Allison N DuRoss¹, Madeleine R Landry¹, Charles R Thomas Jr^{2

3}, Megan J Neufeld¹, Conroy Sun^{1

2}

Affiliations

¹ Department of Pharmaceutical Sciences, Oregon State University, 2730 SW Moody Ave, Portland, OR 97201, USA.
² Department of Radiation Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
³ Radiation Oncology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA.

Abstract

Nanoparticle characterization and in vitro data on the effects of combined PARP inhibition and DNA damage by chemoradiation are shown. This data accompanies the research article "Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer" (DuRoss et al., 2021) Additional characterization of the physiochemical properties of nanoscale metal organic frameworks (nMOFs) comprised of hafnium and 1,4-dicarboxybenzene (Hf-BDC) loaded with temozolomide (TMZ) and talazoparib (Tal) are presented. Toxicity data of the drug-loaded nMOF coated with fucoidan (TT@Hf-BDC-Fuco) in colorectal cancer cells, CT-26, from alamarBlue-based chemoradiation experiments are shown. Experimental methods for the nanoparticle characterization and cell-based assays of the nMOF formulation are presented.

Keywords: DNA Damage; MOF; Nanomedicine; PARP; Radiation therapy.